Mahgoub Abdullahi E, Awuah Dominic, Hussain MurtazaShabbir, Deliwala Smit, Bachuwa Ghassan, Younas Mariam
Internal Medicine, Hurley Medical Center, Flint, USA.
College of Human Medicine, Michigan State University, Lansing, USA.
Cureus. 2022 Feb 13;14(2):e22179. doi: 10.7759/cureus.22179. eCollection 2022 Feb.
A 79-year-old man suddenly developed right lower extremity (RLE) pain and swelling a few days after receiving his 1st dose of the mRNA-1273 COVID-19 vaccine. Despite this, he proceeded to receive the 2nd dose of his mRNA-1273 COVID-19 vaccine. Investigations confirmed extensive acute deep venous thrombosis and a concurrent acute pulmonary embolism. Therapeutic anticoagulation was initiated and he was eventually discharged home on supplemental oxygen. The overall benefits of the vaccine in curbing severe disease overwhelmingly outweigh the handful of cases of reported adverse events. To our knowledge, this is one of the first few cases of provoked venous thrombosis after receiving the mRNA-1273 COVID-19 vaccine during the pharmacovigilance period.
一名79岁男性在接种第一剂mRNA-1273新冠疫苗几天后突然出现右下肢疼痛和肿胀。尽管如此,他还是继续接种了第二剂mRNA-1273新冠疫苗。检查证实存在广泛的急性深静脉血栓形成并伴有急性肺栓塞。开始进行治疗性抗凝,最终他在家中依靠补充氧气出院。疫苗在控制严重疾病方面的总体益处远远超过少数报告的不良事件病例。据我们所知,这是药物警戒期内接种mRNA-1273新冠疫苗后引发静脉血栓形成的首批病例之一。